Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
0.7495
+0.0117 (1.59%)
Feb 6, 2026, 12:34 PM EST - Market open
Genenta Science Employees
Genenta Science had 13 employees as of December 31, 2024. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$785,995
Market Cap
17.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | -1 | -7.14% |
| Dec 31, 2023 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| Lunai Bioworks | 29 |
| IN8bio | 17 |
| Quantum BioPharma | 17 |
| VYNE Therapeutics | 13 |
| FibroBiologics | 13 |
| Lexaria Bioscience | 7 |
| NanoViricides | 7 |
GNTA News
- 10 days ago - Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments - Benzinga
- 10 days ago - Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator - GlobeNewsWire
- 7 weeks ago - Genenta Science Provides Update on CEO Ownership - GlobeNewsWire
- 2 months ago - Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - GlobeNewsWire
- 3 months ago - Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating - Seeking Alpha
- 3 months ago - Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production - GlobeNewsWire
- 7 months ago - Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals - GlobeNewsWire